about
Present and future in the treatment of diabetic kidney diseaseBenefits of healthy adipose tissue in the treatment of diabetes.Activation of glycogen synthase kinase 3β ameliorates diabetes-induced kidney injury.Apelin promotes diabetic nephropathy by inducing podocyte dysfunction via inhibiting proteasome activities.Adipokines mediate inflammation and insulin resistanceThe antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo.ATF3 Protects against LPS-Induced Inflammation in Mice via Inhibiting HMGB1 Expression.Adipokines protecting CKD.The Effect of Aerobic Exercise Training on Plasma Apelin Levels and Pain Threshold in T1DM Rats.Therapeutic implications of peptide interactions with G-protein-coupled receptors in diabetic vasculopathy.Therapeutic approaches to diabetic nephropathy--beyond the RAS.High Glucose-Induced Hypomethylation Promotes Binding of Sp-1 to Myo-Inositol Oxygenase: Implication in the Pathobiology of Diabetic Tubulopathy.Unsung renal receptors: orphan G-protein-coupled receptors play essential roles in renal development and homeostasis.Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse.Effects of apelin on retinal microglial cells in a rat model of oxygen-induced retinopathy of prematurity.Apelin/APJ system: A novel potential therapy target for kidney disease.Effect of apelin hormone on renal ischemia/reperfusion induced oxidative damage in rats.Apelinergic System Structure and Function.The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer.
P2860
Q26864133-FBB33D79-9B71-4220-9E22-69EE9E08D001Q34023537-EAB9A035-B56A-4ECE-81A7-339B6F85308EQ34737936-11C21F30-8254-4840-BF5D-98E8BDA3D053Q36057513-0D9C7468-32EA-4F84-B38E-3D16EAECD404Q36920864-001ACFD5-CD34-46AC-868E-32B09DCD8539Q37142515-4294E321-15D9-4369-BBC0-2853831E95E4Q37162933-26CAC1AC-7005-4506-8934-0A4BE61D6622Q37270838-1B680568-56B1-4AC2-90E2-37F0E37B069BQ37597780-EF5BA15B-6E12-4578-8E66-EBB646FE433FQ38196857-EC57E38E-9DFB-4DB8-B71E-0E2E957D715CQ38209811-44854A0E-05A5-4DD1-AA08-90EBA3AD8465Q38716178-266E274A-BA7A-45C6-A53F-C78D01FEE775Q38971764-6CC43A5C-6870-461A-9106-E1D1D81C18EBQ43876702-1521DBDD-CA10-454F-9664-C3D333D5C1F7Q47578701-6FED2F58-2F38-49BA-B9CC-85E16BFD5D6FQ47933922-207C249E-2B35-49AB-A73B-54EB1CA2F898Q53097959-705F0002-0D14-4083-A093-39AF536D8773Q53468087-ECC45D26-4EF7-4D85-BFCE-4D399EB073A2Q54948644-1F7BC07E-28C4-4A0D-B34E-8A83A526CE60
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Apelin retards the progression of diabetic nephropathy
@ast
Apelin retards the progression of diabetic nephropathy
@en
type
label
Apelin retards the progression of diabetic nephropathy
@ast
Apelin retards the progression of diabetic nephropathy
@en
prefLabel
Apelin retards the progression of diabetic nephropathy
@ast
Apelin retards the progression of diabetic nephropathy
@en
P2093
P2860
P1476
Apelin retards the progression of diabetic nephropathy
@en
P2093
Denis Feliers
Rita C Cavaglieri
Robert T Day
P2860
P304
P356
10.1152/AJPRENAL.00306.2012
P577
2013-01-09T00:00:00Z